NasdaqCM:RPIDLife Sciences
Rapid Micro Biosystems (RPID) Margin Pressure Persists As Q4 Loss Deepens Despite Revenue Gain
Rapid Micro Biosystems (RPID) just posted its FY 2025 results with Q4 revenue of US$11.3 million and a basic EPS loss of US$0.28, alongside a Q4 net loss of US$12.5 million. The company has seen quarterly revenue move from US$8.2 million in Q4 FY 2024 to US$11.3 million in Q4 FY 2025. Over the same period, basic EPS shifted from a loss of US$0.22 to a loss of US$0.28, and trailing 12 month EPS for Q3 FY 2025 sits at a loss of US$1.00 on net losses of US$44.3 million. For investors, the story...